Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06923761	TitleEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial – 1)	Fase Fase 1	Date Added 2025-04-11	Ubicación Australia Francia España Reino Unido	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd
NCT ID NCT06508307	TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors	Fase Fase 1	Date Added 2024-07-18	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06515314	TitleHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors	Fase Fase 1	Date Added 2024-07-23	Ubicación China	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06514651	TitleMAQ-001 in Patients With Advanced Solid Tumors	Fase Fase 1	Date Added 2024-07-23	Ubicación Francia	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd
NCT ID NCT06558773	TitleGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.	Fase Fase 2	Date Added 2024-08-19	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06634875	TitleIsunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS)	Fase Fase 2	Date Added 2024-10-10	Ubicación California, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06456515	TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC	Fase No aplicable	Date Added 2024-06-13	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT06149481	TitleEstudio de fase I/II del régimen de inmunoterapia combinada: SX-682, Vacuna TriAdeno, Retifanlimab y Agonista de IL-15 N-803 (STAR15) para el Cáncer Colorrectal Metastásico (CCRm).	Fase Phase 1, Phase 2	Date Added 2023-11-29	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas N-803, Retifanlimab, SX-682	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05990543	TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2023-08-14	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas Nelmastobart and Capecitabine	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06008119	TitleEfficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer	Fase Fase 3	Date Added 2023-08-23	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab, Tunlametinib plus Vemurafenib	Etiquetas MSI-H/ MMRd, MSS/ MMRp

Showing 1 to 10 of 299 entries